GlassScriptPhysician profile
Johnathan W Lewis
NPI 1699741298
$727.41
in general payments reported to CMS, 2019-2025
14 companies · $238 in 2025
The $238 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $38.89 · 2021: $128 · 2022: $175 · 2023: $65.18 · 2024: $82.76 · 2025: $238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $386.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $386.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $182.41 | 2021-2025 | Trelegy Ellipta, Nucala |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $133.72 | 2024-2025 | Caplyta |
| Abbvie INC. | $66.91 | 2021-2022 | |
| Novo Nordisk INC | $56.62 | 2020-2025 | Wegovy |
| Merck Sharp & Dohme LLC | $54.37 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $53.61 | 2022-2023 | |
| Lilly USA, LLC | $40.90 | 2022-2025 | Mounjaro, Zepbound |
| Exact Sciences Corporation | $34.95 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novartis Pharmaceuticals Corporation | $24.99 | 2022 | |
| Boston Scientific Corporation | $20.11 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.99 | 2021 | |
| Janssen Pharmaceuticals, INC | $14.65 | 2020 | |
| Supernus Pharmaceuticals, INC. | $13.98 | 2023 | Qelbree |
| Kowa Pharmaceuticals America, INC. | $13.20 | 2024 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Johnathan Lewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.